key: cord-0714994-8y47uqi3
authors: Ilhan, Harun; Gosewisch, Astrid; Böning, Guido; Völter, Friederike; Zacherl, Mathias; Unterrainer, Marcus; Bartenstein, Peter; Todica, Andrei; Gildehaus, Franz Josef
title: Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
date: 2020-09-22
journal: Eur J Nucl Med Mol Imaging
DOI: 10.1007/s00259-020-05023-2
sha: 7440e0f5756bd700485eac29de5bff5b3eed3473
doc_id: 714994
cord_uid: 8y47uqi3

nan

of 177 Lu-PSMA-617 were highly effective (B). PSA was still decreasing after two additional 177 Lu-PSMA-617 cycles despite increasing PSMA-ligand uptake in PSMA-PET (C). Maintenance therapy using 177 Lu-PSMA-617 was continued until January 2019 with further response (D and E); however, disease progression occurred after watchful waiting and two cycles of 177 Lu-PSMA-I&T (F and G). The patient then received two cycles of 225 Ac-PSMA-I&T and showed encouraging response (H). The main TAT-related side effect was grade 2 xerostomia (grade 2), which was already preexisting after 10 cycles of RLT. No TAT-related grade 3/4 hematological side effects were noted. Further cycles are planned but were suspended due to the COVID-19 crisis upon patient's request.

Different approaches including tandem therapy with 177 Lu or de-escalating doses during consolidation have been proposed for TAT as a trade-off between therapeutic efficacy and tolerable side effects [2, 4] , and further studies investigating 225 Ac-PSMA remain highly important for prostate cancer theranostics.

This article is part of the Topical Collection on Image of the month.

Funding Open Access funding enabled and organized by Projekt DEAL.

All procedures performed in this study involving human participants were in accordance with ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This retrospective evaluation was approved by the local ethic committee (20-178). Written informed consent was obtained prior to the exam.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Targeted radionuclide therapy of prostate cancer-from basic research to clinical perspectives

Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience

Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving (225)Ac-PSMA-617 radioligand therapy

Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study